Enzo Biochem

356 articles about Enzo Biochem

• Enzo Biochem Reports Results of its Annual Meeting of Shareholders

  4/12/2022

  Enzo Biochem, Inc. announced the approval of all proposals presented at its most recent Annual Meeting of Shareholders.

• Enzo Biochem Adjourns Annual Meeting of Shareholders Until April 8, 2022

  4/1/2022

  Enzo Biochem, Inc. today announced its 2021 Annual Meeting of Shareholders (“Annual Meeting”), with respect to Proposal 1, has been adjourned until April 8, 2022 at 9 AM EDT. 

• Enzo Biochem Appoints David Bench and Kara Cannon to New Executive Management Positions

  3/28/2022

  Enzo Biochem, Inc., a leading biosciences and diagnostics company, announced two key appointments to its new management structure.

• Enzo Biochem Reports Second Quarter Fiscal 2022 Result and Provides Leadership and Corporate Updates

  3/14/2022

  Enzo Biochem, Inc (NYSE: ENZ), a leading biosciences and diagnostics company, today reported financial results for the second quarter ended January 31, 2022 and provided a business update on recent corporate and operational developments.

• Enzo Biochem to Report Second Quarter 2022 Financial Results and Business Update on Monday, March 14th

  3/8/2022

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report second quarter 2022 financial results on Monday, March 14, 2022, after the market close.

• Hamid Erfanian and Bradley Radoff Appointed to Enzo Biochem’s Board of Directors

  1/3/2022

  Enzo Biochem, Inc., a leading biosciences and diagnostics company, announced the appointments of Hamid Erfanian and Bradley Radoff to the Company’s Board of Directors, effective immediately.

• Enzo Biochem Reports First Quarter 2022 Financial Results and Provides Business Update

  12/15/2021

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported financial results for the first quarter ended October 31, 2021 and provided a business update on recent corporate and operational developments.

• Enzo Biochem to Report First Quarter 2022 Financial Results and Business Update on Wednesday, December 15th

  12/2/2021

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report first quarter 2022 financial results on Wednesday, December 15, 2021, after the market close.

• ENZO BIOCHEM REPORTS INDUCEMENT AWARDS TO NEW CHIEF EXECUTIVE OFFICER

  11/9/2021

  Enzo Biochem, Inc. announced today that on November 8, 2021, it granted equity awards to Hamid Erfanian.

• 

  BioSpace Movers & Shakers, Oct. 22

  10/22/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• HAMID ERFANAIN NAMED CHIEF EXECUTIVE OFFICER OF ENZO BIOCHEM TO ACCELERATE EXPANSION AND COMMERCIALIZATION OF KEY DIAGNOSTIC PLATFORMS

  10/18/2021

  Dr. Elazar Rabbani to remain Chairperson of the Board and will assume new role as Chief Scientific Officer

• Enzo Biochem Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

  10/12/2021

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported operating results for the fiscal year and fourth quarter ended July 31, 2021 and provided a business update on recent corporate and operational developments.

• Enzo Biochem to Report Fourth Quarter and Full Year 2021 Financial Results and Business Update on Tuesday, October 12th

  9/28/2021

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report fourth quarter and fiscal year 2021 financial results on Tuesday, October 12, 2021, before the market open.

• Enzo Biochem To Present at The H.C. Wainwright 23rd Annual Global Investment Conference

  9/2/2021

  Enzo Biochem, Inc., a leading biosciences and diagnostics company, announced that management will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually from September 13th - 15th.

• ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR RAPID EXTRACTION METHOD ON PROPRIETARY TEST SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2

  7/20/2021

  Enzo Biochem, Inc. announced today that it has received an expansion of its FDA Emergency Use Authorization (EUA) for the Company’s rapid extraction method on its proprietary test system for the detection of coronavirus SARS-CoV-2 including the genetic variants that are now proliferating globally.

• Enzo Biochem Announces Online Service with TrustAssure to Schedule Timely PCR Testing Required for International Travel

  6/15/2021

  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), today announced a new collaboration to provide rapid access in New York and New Jersey to COVID-19 PCR testing that will be required for international travel from the U.S. to destinations around the world. 

• Enzo Biochem Reports Third Quarter Fiscal 2021 Results

  6/9/2021

  Enzo Biochem, Inc., a leading biosciences and diagnostics company, reported operating results for the third quarter ended April 30, 2021 and provided a business update on recent corporate and operational developments.

• Enzo Biochem to Report Third Quarter 2021 Financial Results on Wednesday, June 9Conference Call and Webcast Scheduled for June 9, 2021, 4:30 pm ET

  6/1/2021

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report third quarter 2021 financial results on Wednesday, June 9, 2021, after the market close.

• Enzo’s Universal AMPICOLLECT™ Used on GENFLEX® Molecular Platform Cleared for Distribution by FDA Under Emergency Use Authorization

  4/21/2021

  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Food and Drug Administration (“FDA”) has cleared its AMPICOLLECT™ Sample Collection kit (manufactured under GMP) for distribution under Emergency Use Authorization.

• ENZO BIOCHEM TO PRESENT AT THE KEYBANC CAPITAL MARKETS' LIFE SCIENCES & MEDTECH INVESTOR FORUM

  3/17/2021

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that management will present at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum, Tuesday March 23rd at 10:45am ET.